

IHL675ARAPHII RHEUMATOID ARTHRITIS STUDY

WHAT IS THE STUDY ABOUT?

This study aims to test the effectiveness of IHL-675A against placebo in the treatment of rheumatoid arthritis. The investigation treatment (IHL-675A) is a capsule that contains cannabidiol (CBD) and hydroxychloroquine. Both CBD and hydroxychloroquine have been shown to have anti-inflammatory properties which may help reduce pain and improve function associated with rheumatoid arthritis.

WHAT IS INVOLVED?

During the study you will be assigned to 1 of 4 groups: 1) the study medication (IHL675A), 2) CBD by itself, 3) hydroxychloroquine by itself, or 4) placebo. You will not know which treatment you are taking until after the study has ended.

Throughout the study you will attend 8 visits at a research center in Broadmeadow. At these visits a study doctor will ask about your general health and experience with rheumatoid arthritis and have you fill out questionnaires. Blood tests and ECGs will be performed to assess your general health and how the study medication may be affecting you.

HOW TO FIND OUT MORE

If you are interested in the trial, contact us using the details below. A member of the study team will discuss the study to see if it may be suitable for you.

ARE THERE ANY COSTS ASSOCIATED?

There will be no additional costs to you for participating in the study. To compensate you for travel time, you will be reimbursed \$100 per study visit.

Contact us



www.genesisresearchservices.com/join-a-trial



4985 1860

genesis
researchservices